Comparator supply for NCT02112916
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Sponsor: National Cancer Institute (NCI) (NIH). Phase: PHASE3. Status: Active Not Recruiting. Countries: United States, Australia, Canada, New Zealand. Last update posted 2026-10-21.
Registry record: https://clinicaltrials.gov/study/NCT02112916.
Canadian-labelled bortezomib
12 marketed Canadian product(s) from 9 manufacturer(s) contain bortezomib (bortezomib mannitol boronic ester). Available strengths: 2.5 MG, 3.5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cyclophosphamide
12 marketed Canadian product(s) from 4 manufacturer(s) contain cyclophosphamide. Available strengths: 1000 MG, 200 MG, 2000 MG, 25 MG, 50 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cyclophosphamide monohydrate
12 marketed Canadian product(s) from 4 manufacturer(s) contain cyclophosphamide. Available strengths: 1000 MG, 200 MG, 2000 MG, 25 MG, 50 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cytarabine
3 marketed Canadian product(s) from 3 manufacturer(s) contain cytarabine. Available strengths: 100 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled daunorubicin
3 marketed Canadian product(s) from 3 manufacturer(s) contain daunorubicin (daunorubicin hydrochloride). Available strengths: 20 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled dexamethasone
11 marketed Canadian product(s) from 6 manufacturer(s) contain dexamethasone. Available strengths: 0.1 %, 0.5 MG, 0.7 MG, 10 MG, 2 MG, 4 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled dexamethasone intensol
11 marketed Canadian product(s) from 6 manufacturer(s) contain dexamethasone. Available strengths: 0.1 %, 0.5 MG, 0.7 MG, 10 MG, 2 MG, 4 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled doxorubicin
7 marketed Canadian product(s) from 5 manufacturer(s) contain doxorubicin hydrochloride. Available strengths: 150 MG, 2 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled doxorubicin hydrochloride
7 marketed Canadian product(s) from 5 manufacturer(s) contain doxorubicin hydrochloride. Available strengths: 150 MG, 2 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled etoposide
3 marketed Canadian product(s) from 3 manufacturer(s) contain etoposide. Available strengths: 20 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled hydrocortisone 21-sodium succinate
6 marketed Canadian product(s) from 3 manufacturer(s) contain hydrocortisone. Available strengths: 1 %, 10 MG, 20 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled hydrocortisone na succinate
6 marketed Canadian product(s) from 3 manufacturer(s) contain hydrocortisone. Available strengths: 1 %, 10 MG, 20 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled hydrocortisone sodium succinate
6 marketed Canadian product(s) from 3 manufacturer(s) contain hydrocortisone. Available strengths: 1 %, 10 MG, 20 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled ifosfamide
2 marketed Canadian product(s) from 1 manufacturer(s) contain ifosfamide. Available strengths: 1 G, 3 G. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled leucovorin
9 marketed Canadian product(s) from 6 manufacturer(s) contain leucovorin (leucovorin calcium). Available strengths: 10 MG, 1000 MG, 5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled mercaptopurine
2 marketed Canadian product(s) from 2 manufacturer(s) contain mercaptopurine. Available strengths: 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled methotrexate
3 marketed Canadian product(s) from 3 manufacturer(s) contain methotrexate. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled methotrexate lpf
3 marketed Canadian product(s) from 3 manufacturer(s) contain methotrexate. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled methotrexate methylaminopterin
3 marketed Canadian product(s) from 3 manufacturer(s) contain methotrexate. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled pegaspargase
1 marketed Canadian product(s) from 1 manufacturer(s) contain pegaspargase. Available strengths: 750 UNIT. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled thioguanine
1 marketed Canadian product(s) from 1 manufacturer(s) contain thioguanine. Available strengths: 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled thioguanine hemihydrate
1 marketed Canadian product(s) from 1 manufacturer(s) contain thioguanine. Available strengths: 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled thioguanine hydrate
1 marketed Canadian product(s) from 1 manufacturer(s) contain thioguanine. Available strengths: 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled vincristine
2 marketed Canadian product(s) from 2 manufacturer(s) contain vincristine sulfate. Available strengths: 1 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled vincristine sulfate
2 marketed Canadian product(s) from 2 manufacturer(s) contain vincristine sulfate. Available strengths: 1 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled bortezomib as a trial comparator?
Yes. We source Canadian-marketed bortezomib under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT02112916.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1 (431) 588-9055.